Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.69 |
| ▸ | CCR1 | P32246 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | DDT | P30046 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757209 | 0.87 | ELANE (0.79) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5760891 | 0.86 | ELANE (0.75) | ELANECCR1ALDH1A1DDT | |
| SCHEMBL5758770 | 0.86 | ELANE (0.80) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5757208 | 0.85 | ELANE (0.50) | ELANEALDH1A1TNKSPARP1TNKS2 | |
| SCHEMBL5756606 | 0.85 | ELANE (0.79) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL561813 | 0.85 | ELANE (0.51) | ELANECCR1TNKSPARP1TNKS2 | |
| SCHEMBL11895008 | 0.85 | ELANE (0.51) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5755788 | 0.85 | ELANE (0.79) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5444649 | 0.84 | ELANE (0.49) | ELANECCR1TNKSPARP1TNKS2 | |
| SCHEMBL5756979 | 0.84 | ELANE (0.78) | ELANECCR1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
| CN-1711243-A | 2-pyridone derivatives as inhibitors of neutrophil elastase | ASTRAZENECA AB (SE) | 2005-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CCR1 186/4885KDM4E 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.